Last reviewed · How we verify
aspirin alone
Aspirin, marketed by UMC Utrecht, is a well-established drug with a key composition patent expiring in 2028. Its primary strength lies in its long-standing use and broad acceptance across multiple indications. The primary risk is the potential increase in generic competition following the patent expiry in 2028.
At a glance
| Generic name | aspirin alone |
|---|---|
| Sponsor | UMC Utrecht |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Aspirin to Target Arterial Events in Chronic Kidney Disease (PHASE3)
- SIMPLAAFY Clinical Trial (NA)
- Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone (PHASE3)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- aspirin alone CI brief — competitive landscape report
- aspirin alone updates RSS · CI watch RSS
- UMC Utrecht portfolio CI